PAI
ALXN

Pittenger & Anderson Inc’s Alexion Pharmaceuticals ALXN Stock Holding History

Pittenger & Anderson Inc’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q3 		– Sell
-100
Closed -$18K – 457
2015
Q2 		$18K Buy
+100
New +$17.3K ﹤0.01% 361

Other funds holding ALXN

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Pittenger & Anderson Inc's ALXN Position: Q3 2015 in Review

Pittenger & Anderson Inc sold out of Alexion Pharmaceuticals (ALXN) in Q3 2015, closing a stake of 100 shares — an estimated $18K sold.

Pittenger & Anderson Inc first reported a position in ALXN in Q2 2015 and held it in 1 quarter. The position peaked at $18K in Q2 2015. 513 funds tracked by Wall St. Rank hold ALXN as of Q3 2015.

  • Pittenger & Anderson Inc reported no remaining Alexion Pharmaceuticals position as of Q3 2015 after selling out during the quarter.
  • Pittenger & Anderson Inc sold 100 Alexion Pharmaceuticals shares in Q3 2015, an estimated $18K.
  • Pittenger & Anderson Inc first reported a position in Alexion Pharmaceuticals in Q2 2015 and held it in 1 quarter.
  • Pittenger & Anderson Inc's Alexion Pharmaceuticals position peaked at $18K in Q2 2015.
  • 513 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q3 2015.

Based on Pittenger & Anderson Inc's 13F filing for Q3 2015, filed 10 Nov 2015.